Unknown

Dataset Information

0

Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans.

ABSTRACT: Recently, novel highly pathogenic avian influenza H5Nx viruses (clade 2.3.4.4) caused outbreaks in US poultry. We evaluated the potential of a stockpiled A(H5N1) A/Anhui/1/2005 (clade 2.3.4) vaccine to elicit cross-reactive antibody responses to these emerging viruses. Sera from subjects who received 2 doses of MF59-adjuvanted A/Anhui/1/2005, or 1 dose of MF59-adjuvanted A/Anhui/1/2005 following priming with a clade 1 vaccine were characterized by microneutralization assays and modified hemagglutination inhibition (HI) assays. Only heterologous prime-boost vaccination induced modest cross-reactive HI antibody responses to H5Nx viruses. Heterologous prime-boost may provide a more effective vaccination strategy to broaden the antibody responses to emerging viruses.

SUBMITTER: Levine MZ 

PROVIDER: S-EPMC5853660 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans.

Levine Min Z MZ   Holiday Crystal C   Liu Feng F   Jefferson Stacie S   Gillis Eric E   Bellamy Abbie R AR   Tumpey Terrence T   Katz Jacqueline M JM  

The Journal of infectious diseases 20170901 suppl_4

Recently, novel highly pathogenic avian influenza H5Nx viruses (clade 2.3.4.4) caused outbreaks in US poultry. We evaluated the potential of a stockpiled A(H5N1) A/Anhui/1/2005 (clade 2.3.4) vaccine to elicit cross-reactive antibody responses to these emerging viruses. Sera from subjects who received 2 doses of MF59-adjuvanted A/Anhui/1/2005, or 1 dose of MF59-adjuvanted A/Anhui/1/2005 following priming with a clade 1 vaccine were characterized by microneutralization assays and modified hemagglu  ...[more]

Similar Datasets

Unknown Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost.
| S-EPMC6541649 | biostudies-literature
Unknown Cross-Reactivity Conferred by Homologous and Heterologous Prime-Boost A/H5 Influenza Vaccination Strategies in Humans: A Literature Review.
| S-EPMC8708856 | biostudies-literature
Unknown An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults.
| S-EPMC5780732 | biostudies-literature
Unknown Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations.
| S-EPMC9750882 | biostudies-literature
Unknown Heterologous prime-boost strategies for COVID-19 vaccines.
| S-EPMC8754745 | biostudies-literature
Unknown A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly.
| S-EPMC2976095 | biostudies-literature
Unknown Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses.
| S-EPMC3694142 | biostudies-other
Unknown Heterologous prime-boost vaccination with H3N2 influenza viruses of swine favors cross-clade antibody responses and protection.
| S-EPMC5604745 | biostudies-literature
Unknown Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
| S-EPMC8115940 | biostudies-literature
Unknown Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of age.
| S-EPMC4224137 | biostudies-literature